Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Other Non-Current Assets (2022 - 2025)

Taysha Gene Therapies' Other Non-Current Assets history spans 4 years, with the latest figure at $184000.0 for Q3 2025.

  • For Q3 2025, Other Non-Current Assets fell 92.92% year-over-year to $184000.0; the TTM value through Sep 2025 reached $184000.0, down 92.92%, while the annual FY2024 figure was $2.2 million, 17.27% down from the prior year.
  • Other Non-Current Assets for Q3 2025 was $184000.0 at Taysha Gene Therapies, down from $186000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $2.6 million in Q1 2022 and bottomed at $184000.0 in Q3 2025.
  • The 4-year median for Other Non-Current Assets is $2.6 million (2023), against an average of $2.1 million.
  • The largest annual shift saw Other Non-Current Assets skyrocketed 97.57% in 2023 before it tumbled 92.92% in 2025.
  • A 4-year view of Other Non-Current Assets shows it stood at $1.3 million in 2022, then surged by 97.57% to $2.6 million in 2023, then fell by 17.27% to $2.2 million in 2024, then tumbled by 91.45% to $184000.0 in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Other Non-Current Assets are $184000.0 (Q3 2025), $186000.0 (Q2 2025), and $2.2 million (Q1 2025).